PsychonautWiki Archive

1B-LSD: Difference between revisions

← Older edit
>LockPicker
→Legal status: added singapore
>Utaninja
→Subjective effects: 1p lsd page has same message without a citation needed
 
(8 intermediate revisions by 7 users not shown)
Line 1: Line 1:
{{SummarySheet}}
{{SummarySheet}}
{{SubstanceBox/1B-LSD}}  
{{SubstanceBox/1B-LSD}}
 
'''1-Butanoyl-''d''-lysergic acid diethylamide''' (also known as '''1B-LSD''') is a novel [[Psychoactive class::psychedelic]] substance of the [[Chemical class::lysergamide]] class.  
'''1-Butanoyl-''d''-lysergic acid diethylamide''' (also known as '''1B-LSD''') is a novel [[Psychoactive class::psychedelic]] substance of the [[Chemical class::lysergamide]] class.  
1B-LSD is closely related to [[LSD]] and [[1P-LSD]] and is reported to produce near-identical effects.  
1B-LSD is closely related to [[LSD]] and [[1P-LSD]] and is reported to produce near-identical effects. 1B-LSD has been found to be around 14% as potent as LSD and expresses itself at the same 5-HT<sub>2A</sub> receptor.<ref name=":0">{{cite journal | vauthors=((Brandt, S. D.)), ((Kavanagh, P. V.)), ((Westphal, F.)), ((Stratford, A.)), ((Elliott, S. P.)), ((Dowling, G.)), ((Wallach, J.)), ((Halberstadt, A. L.)) | journal=Drug Testing and Analysis | title=Return of the lysergamides. Part V: Analytical and behavioural characterization of 1‐butanoyl‐ d ‐lysergic acid diethylamide (1B‐LSD) | volume=11 | issue=8 | pages=1122–1133 | date= August 2019 | url=https://onlinelibrary.wiley.com/doi/10.1002/dta.2613 | issn=1942-7603 | doi=10.1002/dta.2613}}</ref>
Little is known about the pharmacology of 1B-LSD, but it likely produces its psychedelic effects by acting on [[serotonin]] [[receptors]] in the brain.  


The original synthesis date of 1B-LSD is unknown. Unlike most [[research chemicals]], 1B-LSD has no prior record in the scientific literature. The first reports of 1B-LSD use surfaced in 2018 following its appearance on the online [[research chemical]] market.  
The original synthesis date of 1B-LSD is not known. Unlike most [[research chemicals]], 1B-LSD has no prior record in the scientific literature. The first reports of 1B-LSD use surfaced in 2018 following its appearance on the online [[research chemical]] market.  


User reports indicate that the subjective effects of 1B-LSD are extremely similar to those of 1P-LSD. 1B-LSD is theorized to act as a [[prodrug]] for LSD.<ref name="Brandt2015">{{cite journal|last1=Brandt|first1=S. D.|last2=Kavanagh|first2=P. V.|last3=Westphal|first3=F.|last4=Stratford|first4=A.|last5=Elliott|first5=S. P.|last6=Hoang|first6=K.|last7=Wallach|first7=J.|last8=Halberstadt|first8=A. L.|year=2015|title=Return of the lysergamides. Part I: Analytical and behavioural characterization of 1‐propionyl‐d‐lysergic acid diethylamide (1P‐LSD)|journal=Drug Testing and Analysis|volume=8|issue=9|pages=891-902|doi=10.1002/dta.1884|issn=1942-7603}}</ref> The similarities in chemical structure between 1B-LSD and [[LSD]] predicts a near-identical effect profile, likely differing mainly in its rate of absorption and duration. Characteristics effects include [[geometry|geometric visual hallucinations]], [[time distortion]], [[introspection|enhanced introspection]], and [[ego loss]]. Its classical psychedelic effects and favorable tolerability has led it to become popular among novel psychoactive substance users who use it interchangeably with LSD.
[[Subjective effects]] include [[visual geometry]], [[hallucinatory states]], [[time distortion]], [[introspection|enhanced introspection]], [[conceptual thinking]], [[increased music appreciation]], [[euphoria]], and [[ego loss]]. User reports indicate that the subjective effects of 1B-LSD are extremely similar to those of 1P-LSD. 1B-LSD acts as a [[prodrug]] for LSD.<ref name=":1">{{cite journal | vauthors=((Wagmann, L.)), ((Richter, L. H. J.)), ((Kehl, T.)), ((Wack, F.)), ((Bergstrand, M. P.)), ((Brandt, S. D.)), ((Stratford, A.)), ((Maurer, H. H.)), ((Meyer, M. R.)) | journal=Analytical and Bioanalytical Chemistry | title=In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures | volume=411 | issue=19 | pages=4751–4763 | date= July 2019 | url=http://link.springer.com/10.1007/s00216-018-1558-9 | issn=1618-2642 | doi=10.1007/s00216-018-1558-9}}</ref> The similarities in chemical structure between 1B-LSD and [[LSD]] predicts a near-identical effect profile, likely differing mainly in its rate of absorption and duration.  


Very little data exists about the pharmacological properties, metabolism, and toxicity of 1B-LSD. It is presumed to have a similar toxicity and risk profile as [[LSD]], although no evidence currently exists to support this. It is highly advised to use [[harm reduction practices]] if using this substance.
Very little data exists about the pharmacological properties, metabolism, and toxicity of 1B-LSD. It is presumed to have a similar toxicity and risk profile as [[LSD]], although no evidence currently exists to support this. It is highly advised to use [[harm reduction practices]] if using this substance.
Line 14: Line 12:
==History and culture==
==History and culture==
1B-LSD first appeared on the online research chemical market in August 2016.<ref>{{cite web|url=https://trends.google.com/trends/explore?date=all&q=1b-lsd|title=1B-LSD (Google Trends)|access-date=January 1, 2020}}</ref>  
1B-LSD first appeared on the online research chemical market in August 2016.<ref>{{cite web|url=https://trends.google.com/trends/explore?date=all&q=1b-lsd|title=1B-LSD (Google Trends)|access-date=January 1, 2020}}</ref>  
It is unknown who first synthesized 1B-LSD, as the substance does not appear in any academic literature pre-dating its arrival on the research chemical market.<ref name="Brandt2015"></ref>  
It is unknown who first synthesized 1B-LSD, as the substance does not appear in any academic literature pre-dating its arrival on the research chemical market.<ref name="Brandt2015">{{cite journal|last1=Brandt|first1=S. D.|last2=Kavanagh|first2=P. V.|last3=Westphal|first3=F.|last4=Stratford|first4=A.|last5=Elliott|first5=S. P.|last6=Hoang|first6=K.|last7=Wallach|first7=J.|last8=Halberstadt|first8=A. L.|year=2015|title=Return of the lysergamides. Part I: Analytical and behavioural characterization of 1‐propionyl‐d‐lysergic acid diethylamide (1P‐LSD)|journal=Drug Testing and Analysis|volume=8|issue=9|pages=891-902|doi=10.1002/dta.1884|issn=1942-7603}}</ref>  
Interestingly, the future usage of 1-akylated lysergamide derivatives as a means to bypass controlled substance laws banning [[LSD]] as a precursor was foreseen in a DEA report from 1988:
Interestingly, the future usage of 1-akylated lysergamide derivatives as a means to bypass controlled substance laws banning [[LSD]] as a precursor was foreseen in a DEA report from 1988:
{{quote3|text=...a reduction in hallucinogenic activity may become acceptable to the U.S. clandestine chemist when he notes that lysergic acid amide is listed as a Schedule III substance in the CFR; therefore, structurally similar substances of this compound are exempted from the CsA amendment. A lucid argument can then be made that lysergic acid N,N-dimethylamide is derived from lysergic acid amide rather than LSD. Carrying this theme to the next logical step one would then assume that the 1-alkyl and 1-acyl derivatives of the N,N-dimethyl isomer would also not be controlled by the CsA amendment. |author=Donald A. Cooper|source=Future Synthetic Drugs of Abuse, 1988.<ref>{{cite web|last1=Cooper|first1=Donald A.|year=1988|title=Future Synthetic Drugs of Abuse|isbn=978-0-93211-509-6|work=Proceedings of the international symposium on the forensic aspects of controlled substances|page=79|url=https://www.erowid.org/library/books_online/future_synthetic/future_synthetic.shtml}}</ref>}}
{{quote3|text=...a reduction in hallucinogenic activity may become acceptable to the U.S. clandestine chemist when he notes that lysergic acid amide is listed as a Schedule III substance in the CFR; therefore, structurally similar substances of this compound are exempted from the CsA amendment. A lucid argument can then be made that lysergic acid N,N-dimethylamide is derived from lysergic acid amide rather than LSD. Carrying this theme to the next logical step one would then assume that the 1-alkyl and 1-acyl derivatives of the N,N-dimethyl isomer would also not be controlled by the CsA amendment. |author=Donald A. Cooper|source=Future Synthetic Drugs of Abuse, 1988.<ref>{{cite web|last1=Cooper|first1=Donald A.|year=1988|title=Future Synthetic Drugs of Abuse|isbn=978-0-93211-509-6|work=Proceedings of the international symposium on the forensic aspects of controlled substances|page=79|url=https://www.erowid.org/library/books_online/future_synthetic/future_synthetic.shtml}}</ref>}}
Line 27: Line 25:
{{Further|Serotonergic psychedelic}}
{{Further|Serotonergic psychedelic}}
Based on its structural similarity to LSD, 1B-LSD likely acts as a [[Agonist#Agonists|partial agonist]] at the [[Serotonin#The_5-HT_system|5-HT<sub>2A</sub>]] receptor.  
Based on its structural similarity to LSD, 1B-LSD likely acts as a [[Agonist#Agonists|partial agonist]] at the [[Serotonin#The_5-HT_system|5-HT<sub>2A</sub>]] receptor.  
The [[psychedelic]] effects are thought to primarily come from its efficacy at the 5-HT<sub>2A</sub> receptors distributed throughout the brain. 1B-LSD also likely displays binding activity at a wide range of [[monoamine]] receptors, such as those for [[dopamine]] and [[norepinephrine]]. However, there is currently no data to support these claims.
The [[psychedelic]] effects are thought to primarily come from its efficacy at the 5-HT<sub>2A</sub> receptors distributed throughout the brain.<ref name=":0" /> 1B-LSD also likely displays binding activity at a wide range of [[monoamine]] receptors, such as those for [[dopamine]] and [[norepinephrine]]. However, there is currently no data to support these claims.


It has been theorized that [[1B-LSD]] (as well as the acyl homologs [[1P-LSD]] and [[ALD-52]]) is deacylated in the body to LSD by elimination of butyric acid, as shown by studies with human blood serum.<ref>{{cite journal|last1=Wagmann|first1=L.|last2=Richter|first2=L. H. J.|last3=Kehl|first3=T.|last4=Wack|first4=F.|last5=Pettersson Bergstrand|first5=M.|last6=Brandt|first6=S. D.|last7=Stratford|first7=A.|last8=Maurer|first8=H. H.|last9=Meyer|first9=M. R.|year=2019|title=In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures|journal=Analytical and Bioanalytical Chemistry|volume=411|issue=19|pages=4751-4763|doi=10.1007/s00216-018-1558-9|issn=1618-2642}}</ref>
It has been shown that [[1B-LSD]] (as well as the acyl homologs [[1P-LSD]] and [[ALD-52]]) are deacylated in the body via CYP1A2 and CYP3A4 into LSD by elimination of the butyric acid, as shown in studies with both human blood serum and in rats.<ref name=":1" /><ref>{{cite journal|last1=Wagmann|first1=L.|last2=Richter|first2=L. H. J.|last3=Kehl|first3=T.|last4=Wack|first4=F.|last5=Pettersson Bergstrand|first5=M.|last6=Brandt|first6=S. D.|last7=Stratford|first7=A.|last8=Maurer|first8=H. H.|last9=Meyer|first9=M. R.|year=2019|title=In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures|journal=Analytical and Bioanalytical Chemistry|volume=411|issue=19|pages=4751-4763|doi=10.1007/s00216-018-1558-9|issn=1618-2642}}</ref>


==Subjective effects==
==Subjective effects==
Anecdotal reports from many users suggest that the subjective effects of 1B-LSD are so similar to that of [[LSD]] so as to be virtually indistinguishable from one another. In comparison to other psychedelics such as [[psilocybin]], [[LSA]] and [[ayahuasca]], 1B-LSD is significantly more stimulating and fast-paced regarding the specific style of its physical and cognitive effects.  
Anecdotal reports from many users suggest that the subjective effects of 1B-LSD are so similar to that of [[LSD]] so as to be virtually indistinguishable from one another. In comparison to other psychedelics such as [[psilocybin]], [[LSA]] and [[ayahuasca]], 1B-LSD is significantly more stimulating and fast-paced regarding the specific style of its physical and cognitive effects.


{{Preamble/SubjectiveEffects}}
{{Preamble/SubjectiveEffects}}
{{effects/base
{{effects/base


Line 113: Line 112:
*'''[[Effect::Increased music appreciation]]'''
*'''[[Effect::Increased music appreciation]]'''
*'''[[Effect::Increased sense of humor]]'''
*'''[[Effect::Increased sense of humor]]'''
**'''[[Effect::Laughter fits]]''' - This can manifest prominently during a 1B-LSD experience, particularly during the [[Duration#Come up|come up]] phase, often resulting in bouts of uncontrollable giggles and laughter that can form a feedback loop if around others who are also under the influence.
**'''[[Effect::Laughter fits]]''' - This can manifest prominently during a 1B-LSD experience, particularly during the [[Duration#Come up|come up]] phase, often resulting in bouts of uncontrollable giggles and laughter that can form a feedback loop if around others who are also under the influence.{{Citation needed}}
*'''[[Effect::Memory suppression]]'''
*'''[[Effect::Memory suppression]]'''
**'''[[Effect::Ego death]]'''
**'''[[Effect::Ego death]]'''
Line 178: Line 177:
Although no formal studies have been conducted, it is assumed that like LSD itself, 1B-LSD is [[Addiction potential::non-addictive with a low abuse potential]]. There are no literature reports of successful attempts to train animals to self-administer LSD — an animal model predictive of abuse liability — indicating that it does not have the necessary pharmacology to either initiate or maintain dependence.<ref>{{cite journal|last1=Nichols|first1=David E.|author-link=David E. Nichols|year=2004|title=Hallucinogens|journal=Pharmacology & Therapeutics|volume=101|issue=2|pages=131-181|doi=10.1016/j.pharmthera.2003.11.002|issn=0163-7258}}</ref> Likewise, there is virtually no withdrawal syndrome when chronic use of LSD is stopped.{{citation needed}} It is assumed that 1B-LSD shares these properties with LSD.
Although no formal studies have been conducted, it is assumed that like LSD itself, 1B-LSD is [[Addiction potential::non-addictive with a low abuse potential]]. There are no literature reports of successful attempts to train animals to self-administer LSD — an animal model predictive of abuse liability — indicating that it does not have the necessary pharmacology to either initiate or maintain dependence.<ref>{{cite journal|last1=Nichols|first1=David E.|author-link=David E. Nichols|year=2004|title=Hallucinogens|journal=Pharmacology & Therapeutics|volume=101|issue=2|pages=131-181|doi=10.1016/j.pharmthera.2003.11.002|issn=0163-7258}}</ref> Likewise, there is virtually no withdrawal syndrome when chronic use of LSD is stopped.{{citation needed}} It is assumed that 1B-LSD shares these properties with LSD.


Tolerance to the effects of 1B-LSD are built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::5-7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::14 days]] to be back at baseline (in the absence of further consumption). 1B-LSD produces cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the use of 1B-LSD they will have a reduced effect.
Tolerance to the effects of 1B-LSD is built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::5-7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::14 days]] to be back at baseline (in the absence of further consumption). 1B-LSD produces cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the use of 1B-LSD they will have a reduced effect.


===Dangerous interactions===
===Dangerous interactions===
Line 193: Line 192:
*'''Austria''': 1B-LSD is technically not illegal but it may fall under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD, thus making it illegal to supply for human consumption.<ref>{{cite news|publisher=Der Standard|date=September 28, 2011|title=Synthetische Drogen: Neues Gesetz soll "Legal Highs" bekämpfen|trans-title=Synthetic drugs: New law is to combat legal highs|access-date=January 1, 2020|url=https://www.derstandard.at/story/1317018702282/kraeutermischungen-synthetische-drogen-neues-gesetz-soll-legal-highs-bekaempfen|language=de}}</ref><ref>{{cite web|url=https://www.parlament.gv.at/PAKT/VHG/XXIV/ME/ME_00317/imfname_231611.pdf|title=Entwurf: Bundesgesetz,  mit  dem  ein  Bundesgesetz  über  den  Schutz  vor  Gesundheitsgefahren  im Zusammenhang  mit Neuen Psychoaktiven  Substanzen  (Neue-Psychoaktive-Substanzen-Gesetz, NPSG) erlassen und das Suchtmittelgesetz (SMG) geändert wird|access-date=January 1, 2020|language=de}}</ref>
*'''Austria''': 1B-LSD is technically not illegal but it may fall under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD, thus making it illegal to supply for human consumption.<ref>{{cite news|publisher=Der Standard|date=September 28, 2011|title=Synthetische Drogen: Neues Gesetz soll "Legal Highs" bekämpfen|trans-title=Synthetic drugs: New law is to combat legal highs|access-date=January 1, 2020|url=https://www.derstandard.at/story/1317018702282/kraeutermischungen-synthetische-drogen-neues-gesetz-soll-legal-highs-bekaempfen|language=de}}</ref><ref>{{cite web|url=https://www.parlament.gv.at/PAKT/VHG/XXIV/ME/ME_00317/imfname_231611.pdf|title=Entwurf: Bundesgesetz,  mit  dem  ein  Bundesgesetz  über  den  Schutz  vor  Gesundheitsgefahren  im Zusammenhang  mit Neuen Psychoaktiven  Substanzen  (Neue-Psychoaktive-Substanzen-Gesetz, NPSG) erlassen und das Suchtmittelgesetz (SMG) geändert wird|access-date=January 1, 2020|language=de}}</ref>
*'''Germany''': 1B-LSD is controlled under the NpSG (''New Psychoactive Substances Act'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/anlage.html|title=Anlage NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]|access-date=December 10, 2019|language=de}}</ref> as of July 18, 2019.<ref>{{cite web|url=http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl119s1083.pdf|title=Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes|publisher=Bundesanzeiger Verlag|work=Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27|pages=1083-1094|publication-date=July 17, 2019|access-date=January 1, 2020|language=de}}</ref> Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/__4.html|title=§ 4 NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]|access-date=December 10, 2019|language=de}}</ref>
*'''Germany''': 1B-LSD is controlled under the NpSG (''New Psychoactive Substances Act'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/anlage.html|title=Anlage NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]|access-date=December 10, 2019|language=de}}</ref> as of July 18, 2019.<ref>{{cite web|url=http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl119s1083.pdf|title=Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes|publisher=Bundesanzeiger Verlag|work=Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27|pages=1083-1094|publication-date=July 17, 2019|access-date=January 1, 2020|language=de}}</ref> Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/__4.html|title=§ 4 NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]|access-date=December 10, 2019|language=de}}</ref>
*'''Japan''': 1B-LSD is controlled by the Pharmaceutical Affairs Law in Japan, making it illegal to possess or sell.<ref>{{cite web|title=新たに指定された指定薬物の名称|language=ja|url=https://www.mhlw.go.jp/content/11126000/000345410.pdf|publisher=厚生労働省 [Ministry of Health, Labour and Welfare (MHLW)]|access-date=October 18, 2020}}</ref>
*'''Japan''': 1B-LSD is controlled by the Pharmaceutical Affairs Law in Japan, making it illegal to possess or sell.<ref>{{cite web|title=指定薬物を指定する省令が公布されました|language=ja|url=https://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou_iryou/iyakuhin/yakubuturanyou/oshirase/20200826-1.html|publisher=厚生労働省 [Ministry of Health, Labour and Welfare (MHLW)]|access-date=March 25, 2021}}</ref>
*'''Latvia''': 1B-LSD is illegal in Latvia. Although it is not officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1, 2015.<ref>{{cite web|url=http://likumi.lv/doc.php?id=121086|title=Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem|publisher=VSIA Latvijas Vēstnesis|access-date=January 1, 2020|publication-date=November 10, 2005|language=lv}}</ref>
*'''Latvia''': 1B-LSD is illegal in Latvia. Although it is not officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1, 2015.<ref>{{cite web|url=http://likumi.lv/doc.php?id=121086|title=Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem|publisher=VSIA Latvijas Vēstnesis|access-date=January 1, 2020|publication-date=November 10, 2005|language=lv}}</ref>
*'''Lithuania''': 1B-LSD is illegal in Lithuania and is specifically named on the list of illegal substances since June 5, 2019.<ref>{{cite web|url=https://www.e-tar.lt/portal/lt/legalActEditions/TAR.7B3B40DCD13A|title=LR SAM Įsakymas Dėl Narkotinių ir psichotropinių medžiagų sąrašų patvirtinimo|access-date=January 1, 2020|language=lt}}</ref>
*'''Lithuania''': 1B-LSD is illegal in Lithuania and is specifically named on the list of illegal substances since June 5, 2019.<ref>{{cite web|url=https://www.e-tar.lt/portal/lt/legalActEditions/TAR.7B3B40DCD13A|title=LR SAM Įsakymas Dėl Narkotinių ir psichotropinių medžiagų sąrašų patvirtinimo|access-date=January 1, 2020|language=lt}}</ref>
*'''Singapore''': 1P-LSD is a Class A controlled substance.<ref>{{cite web|title=Misuse of Drugs Act: (CHAPTER 185)|url=https://sso.agc.gov.sg/Act/MDA1973|website=sso.agc.gov.sg|date=March 31, 2008|access-date=October 22, 2020}}</ref>  
*'''Singapore''': 1P-LSD is a Class A controlled substance.<ref>{{cite web|title=Misuse of Drugs Act: (CHAPTER 185)|url=https://sso.agc.gov.sg/Act/MDA1973|website=sso.agc.gov.sg|date=March 31, 2008|access-date=October 22, 2020}}</ref>
*'''Sweden''': Following its sale as a [[designer drug]], 1B-LSD was made illegal in Sweden on January 26, 2016.<ref>{{cite web|url=https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2016/januari/31-nya-substanser-klassas-som-narkotika-eller-halsofarlig-vara|title=31 nya substanser klassas som narkotika eller hälsofarlig vara|publisher=Folkhälsomyndigheten [Public Health Agency of Sweden]|access-date=January 1, 2020|publication-date=January 26, 2016|language=sv}}</ref>
*'''Sweden''': Following its sale as a [[designer drug]], 1B-LSD was made illegal in Sweden on January 26, 2016.<ref>{{cite web|url=https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2016/januari/31-nya-substanser-klassas-som-narkotika-eller-halsofarlig-vara|title=31 nya substanser klassas som narkotika eller hälsofarlig vara|publisher=Folkhälsomyndigheten [Public Health Agency of Sweden]|access-date=January 1, 2020|publication-date=January 26, 2016|language=sv}}</ref>
*'''Switzerland''': 1B-LSD can be considered a controlled substance as a defined derivative of Lysergic Acid under Verzeichnis E point 263. It is legal when used for scientific or industrial use.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''Switzerland''': 1B-LSD can be considered a controlled substance as a defined derivative of Lysergic Acid under Verzeichnis E point 263. It is legal when used for scientific or industrial use.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''United Kingdom''': 1B-LSD is illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26, 2016.<ref>{{cite web|url=http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted|title=Psychoactive Substances Act 2016|access-date=January 1, 2020|publisher=UK Government}}</ref>
*'''United Kingdom''': 1B-LSD is illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26, 2016.<ref>{{cite web|url=http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted|title=Psychoactive Substances Act 2016|access-date=January 1, 2020|publisher=UK Government}}</ref>
*'''United States''': Since 1B-LSD can be considered a prodrug for LSD, its possession and sale may be prosecutable in the United States under the Federal Analogue Act.{{citation needed}}
*'''United States''': While 1B-LSD is not explicitly prohibited by law it is however, a prodrug for LSD, meaning its possession and sale may be prosecutable in the United States under the Federal Analogue Act.<ref>{{Citation | title=21 U.S. Code § 813 - Treatment of controlled substance analogues | url=https://www.law.cornell.edu/uscode/text/21/813}}</ref>


==See also==
==See also==
Retrieved from "http://psy.st/wiki/1B-LSD"